These specialized regions detect circulating GLP-1 and GLP-1RAs and relay signals to the hypothalamus, further influencing appetite and body weight regulation
Patients should be aware that GLP-1 medications are initiated and monitored within specialist or primary care diabetes services
GLP-1s Show Promise, but New Uses Arent Here Yet Editorial Sources and Fact-Checking GLP-1 Agonists
Microdosing involves using substantially lower doses than standard therapeutic regimens, falling outside approved prescribing guidance
Postmenopausal women : Already experiencing hormone-related bone loss Adults over 50 : Natural bone loss accelerates with age People with a family history of osteoporosis : Genetic factors play a significant role Those with small body frames : Lower baseline bone mass People experiencing rapid weight loss : Losing more than 1-2 pounds per week Long-term GLP-1 medication users : The longer the use, the greater the potential impact How to Protect Your Bone Health While on GLP-1 Medications Prevention is better than cure
Rosenstock J., Hanefeld M., Gentile S., Aronson R
